Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

Summary

Primary Objective of the trial is to evaluate the efficacy and safety of Isa-VRd-based regimen in transplant-ineligible newly diagnosed multiple myeloma (TI-NDMM) patients receiving treatment in real-world clinical practice in China. And Secondary Objectives is， To assess the MRD negativity rate in Chinese TI-NDMM patients treated with Isa-VRd To assess the safety and tolerability of Isa-VRd in Chinese TI-NDMM patients Participants will: Receive Isatuximab 10 mg/kg iv * Cycle 1: Every weeks on Days 1, 8, 15, and 22 * Cycles 2-8: Every 2 weeks on Days 1 and 15 Receive Bortezomib subcutaneous injection 1.3 mg/m² * Cycles 1-8: Days 1, 8, and 15 of each cycle Receive Lenalidomide oral 25 mg/day * Cycles 1-8: Days 1-21 at 25 mg/day (10 mg/day for patients with creatinine clearance \[CrCl\] ≥30 and \<60 mL/min) Receive Dexamethasone oral 20 mg * Cycles 1-8: Days 1, 8, 15, and 22 of each cycle Following Cycle 8, the investigator may assess and adjust the treatment regimen During the induction phase, efficacy assessment is recommended at each treatment cycle. Patients who achieve ≥CR at the end of induction are recommended to undergo the first MRD monitoring assessment. During the maintenance phase, efficacy assessment is recommended at least every 3 cycles. Patients are recommended to undergo MRD status monitoring (≥CR) every 6 months (i.e., at months 14, 20, and 26) for MRD assessment. During the follow-up period, MRD status monitoring (≥CR) is recommended every 12 months to observe the depth of response.

Eligibility

Inclusion Criteria:

* Age ≥18 years
* Newly diagnosed transplant-ineligible multiple myeloma patients as assessed by investigator, specifically referring to CSCO guidelines
* Must meet corresponding laboratory test results (refer to restrictions in package inserts of combination drugs):

  * Absolute neutrophil count (ANC) ≥1.0×10⁹/L
  * Platelet count ≥50×10⁹/L
  * Calculated creatinine clearance ≥30 mL/min (using Cockcroft-Gault formula)
  * Total bilirubin ≤3× upper limit of normal (ULN)
* TI-NDMM patients intended for Isa-VRd regimen treatment as determined by investigator judgment, independent of study objectives Signed informed consent form (by patient or their legal representative)

Exclusion Criteria:

* Patients currently participating in other interventional clinical studies
* Patients with known severe hypersensitivity reactions to Isatuximab or any other excipients
* Severe bacteremia at the time of administration
* Currently uncontrolled cardiovascular disease, including:

  * Uncontrolled hypertension
  * Uncontrolled arrhythmia
  * Uncontrollable congestive heart failure
  * Unstable angina
* Patients with peripheral neuropathy ≥Grade 2
* Active infectious disease, known human immunodeficiency virus (HIV) positivity, active hepatitis B or hepatitis C
* Patients who are currently pregnant
* Patients who, at the physician's discretion, are unable to tolerate any drug in the combination regimen

Conditions2

Interventions4

Related trials

• A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03) — Nanjing IASO Biotechnology Co., Ltd.
• A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM. — Karyopharm Therapeutics Inc
• A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant — Sinocelltech Ltd.
• Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients — North Estonia Medical Centre
• Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis — Jin Lu, MD
• Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia — Instituto do Cancer do Estado de São Paulo
• Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease — Wei Zhao
• GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5 — University of Heidelberg Medical Center

Browse More Trials